Alzheimer's drug benefits 'too small' to offer on NHS, NICE finds
By Lee Peart 19 June 2025
The benefits from Alzheimer’s drugs donanemab and lecanemab are too small to justify the additional costs to the NHS, NICE has found.
Occupational Therapy Lead
£48,226 - £51,356 per annum
Gloucester, Gloucestershire£48,226 - £51,356 per annum
Occupational Therapist
£37,280 - £40,777 per annum
Gloucester, Gloucestershire £37,280 - £40,777 per annum
Social Worker Relief Emergency Duty Team
£38,220 - £42,839 per annum pro rata
Selby, North Yorkshire£38,220 - £42,839 per annum pro rata
Most Read News
- Former NHS employee jailed for four years for lying about qualifications
- Councils call for greater powers to boost vaccination rates
- NHS faces collapse without social care reform, says Burnham
- Joint chief executive appointed head of third trust
- BREAKING NEWS: Burnham appoints Yvette Cooper as health secretary
Occupational Therapy Lead
£48,226 - £51,356 per annum
Gloucester, Gloucestershire£48,226 - £51,356 per annum
Occupational Therapist
£37,280 - £40,777 per annum
Gloucester, Gloucestershire £37,280 - £40,777 per annum
Social Worker Relief Emergency Duty Team
£38,220 - £42,839 per annum pro rata
Selby, North Yorkshire£38,220 - £42,839 per annum pro rata
Most Read News
- Former NHS employee jailed for four years for lying about qualifications
- Councils call for greater powers to boost vaccination rates
- NHS faces collapse without social care reform, says Burnham
- Joint chief executive appointed head of third trust
- BREAKING NEWS: Burnham appoints Yvette Cooper as health secretary
©2026 Hemming Group Limited. Registered in England and Wales. Registered No: 490200. VAT number GB342 023 408
